|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gomella LG, Singh J, Lallas C and Trabulsi
EJ: Hormone therapy in the management of prostate cancer:
Evidence-based approaches. Ther Adv Urol. 2:171–181. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fidler IJ: The pathogenesis of cancer
metastasis: The ‘seed and soil’ hypothesis revisited. Nat Rev
Cancer. 3:453–458. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Weigelt B, Peterse JL and van't Veer LJ:
Breast cancer metastasis: Markers and models. Nat Rev Cancer.
5:591–602. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gupta GP and Massague J: Cancer
metastasis: Building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kozomara A and Griffiths-Jones S: miRBase:
Integrating microRNA annotation and deep-sequencing data. Nucleic
Acids Res. 39:D152–D157. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hummel R, Hussey DJ and Haier J:
MicroRNAs: Predictors and modifiers of chemo- and radiotherapy in
different tumour types. Eur J Cancer. 46:298–311. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lim LP, Lau NC, Garrett-Engele P, Grimson
A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim S, Lee UJ, Kim MN, Lee EJ, Kim JY, Lee
MY, Choung S, Kim YJ and Choi YC: MicroRNA miR-199a* regulates the
MET proto-oncogene and the downstream extracellular
signal-regulated kinase 2 (ERK2). J Biol Chem. 283:18158–18166.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yuva-Aydemir Y, Simkin A, Gascon E and Gao
FB: MicroRNA-9: functional evolution of a conserved small
regulatory RNA. RNA Biol. 8:557–564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shibata M, Kurokawa D, Nakao H, Ohmura T
and Aizawa S: MicroRNA-9 modulates cajal-retzius cell
differentiation by suppressing foxg1 expression in mouse medial
pallium. J Neurosci. 28:10415–10421. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Leucht C, Stigloher C, Wizenmann A, Klafke
R, Folchert A and Bally-Cuif L: MicroRNA-9 directs late organizer
activity of the midbrain-hindbrain boundary. Nat Neurosci.
11:641–648. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Delaloy C, Liu L, Lee JA, Su H, Shen F,
Yang GY, Young WL, Ivey KN and Gao FB: MicroRNA-9 coordinates
proliferation and migration of human embryonic stem cell-derived
neural progenitors. Cell Stem Cell. 6:323–335. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pietrzykowski AZ, Friesen RM, Martin GE,
Puig SI, Nowak CL, Wynne PM, Siegelmann HT and Treistman SN:
Posttranscriptional regulation of BK channel splice variant
stability by miR-9 underlies neuroadaptation to alcohol. Neuron.
59:274–287. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ma L, Young J, Prabhala H, Pan E, Mestdagh
P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S,
et al: miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin
and cancer metastasis. Nat Cell Biol. 12:247–256. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lehmann U, Hasemeier B, Christgen M,
Müller M, Römermann D, Länger F and Kreipe H: Epigenetic
inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J
Pathol. 214:17–24. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Laios A, O'Toole S, Flavin R, Martin C,
Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, et al:
Potential role of miR-9 and miR-223 in recurrent ovarian cancer.
Mol Cancer. 7:352008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nie K, Gomez M, Landgraf P, Garcia JF, Liu
Y, Tan LH, Chadburn A, Tuschl T, Knowles DM and Tam W:
MicroRNA-mediated down-regulation of PRDM1/blimp-1 in
hodgkin/reed-sternberg cells: A potential pathogenetic lesion in
hodgkin lymphomas. Am J Pathol. 173:242–252. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu Q, Shen W, Huang H, Liu J, Zhang J,
Huang X, Wu J and Shi Y: Insight into the binding properties of
MEKK3 PB1 to MEK5 PB1 from its solution structure. Biochemistry.
46:13478–13489. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nakamura K, Kimple AJ, Siderovski DP and
Johnson GL: PB1 domain interaction of p62/sequestosome 1 and MEKK3
regulates NF-kappaB activation. J Biol Chem. 285:2077–2089. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fan Y, Ge N, Wang X, Sun W, Mao R, Bu W,
Creighton CJ, Zheng P, Vasudevan S, An L, et al: Amplification and
over-expression of MAP3K3 gene in human breast cancer promotes
formation and survival of breast cancer cells. J Pathol. 232:75–86.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Deng Y, Yang J, McCarty M and Su B: MEKK3
is required for endothelium function but is not essential for tumor
growth and angiogenesis. Am J Physiol Cell Physiol.
293:C1404–C1411. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Alimirah F, Chen J, Basrawala Z, Xin H and
Choubey D: DU-145 and PC-3 human prostate cancer cell lines express
androgen receptor: Implications for the androgen receptor functions
and regulation. FEBS Lett. 580:2294–2300. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sramkoski RM, Pretlow TG II, Giaconia JM,
Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D and
Jacobberger JW: A new human prostate carcinoma cell line, 22Rv1. In
Vitro Cell Dev Biol Anim. 35:403–409. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Korenchuk S, Lehr JE, Mclean L, Lee YG,
Whitney S, Vessella R, Lin DL and Pienta KJ: VCaP, a cell-based
model system of human prostate cancer. In Vivo. 15:163–168.
2001.PubMed/NCBI
|
|
29
|
Thalmann GN, Anezinis PE, Chang SM, Zhau
HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC and Chung LW:
Androgen-independent cancer progression and bone metastasis in the
LNCaP model of human prostate cancer. Cancer Res. 54:2577–2581.
1994.PubMed/NCBI
|
|
30
|
Claxton K, Martin S, Soares M, Rice N,
Spackman E, Hinde S, Devlin N, Smith PC and Sculpher M: Methods for
the estimation of the National Institute for Health and Care
Excellence cost-effectiveness threshold. Health Technol Assess.
19:1–503. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jayandharan GR, Zhong L, Sack BK, Rivers
AE, Li M, Li B, Herzog RW and Srivastava A: Optimized
adeno-associated virus (AAV)-protein phosphatase-5 helper viruses
for efficient liver transduction by single-stranded AAV vectors:
Therapeutic expression of factor IX at reduced vector doses. Hum
Gene Ther. 21:271–283. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hasan R, Sharma R, Saraya A, Chattopadhyay
TK, DattaGupta S, Walfish PG, Chauhan SS and Ralhan R: Mitogen
activated protein kinase kinase kinase 3 (MAP3K3/MEKK3)
overexpression is an early event in esophageal tumorigenesis and is
a predictor of poor disease prognosis. BMC Cancer. 14:22014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Samanta AK, Huang HJ, Bast RC Jr and Liao
WS: Overexpression of MEKK3 confers resistance to apoptosis through
activation of NFkappaB. J Biol Chem. 279:7576–7583. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu Y, Xu X, Xu X, Li S, Liang Z, Hu Z, Wu
J, Zhu Y, Jin X, Wang X, et al: MicroRNA-193a-3p inhibits cell
proliferation in prostate cancer by targeting cyclin D1. Oncol
Lett. 14:5121–5128. 2017.PubMed/NCBI
|
|
36
|
Huang S, Wa Q, Pan J, Peng X, Ren D, Huang
Y, Chen X and Tang Y: Downregulation of miR-141-3p promotes bone
metastasis via activating NF-κB signaling in prostate cancer. J Exp
Clin Cancer Res. 36:1732017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cao XQ, Lu HS, Zhang L, Chen LL and Gan
MF: MEKK3 and survivin expression in cervical cancer: Association
with clinicopathological factors and prognosis. Asian Pac J Cancer
Prev. 15:5271–5276. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen Q, Lu HS, Gan MF, Chen LX, He K, Fan
GM and Cao XQ: Expression and prognostic role of MEKK3 and pERK in
patients with renal clear cell carcinoma. Asian Pac J Cancer Prev.
16:2495–2499. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Santoro R, Zanotto M, Carbone C, Piro G,
Tortora G and Melisi D: MEKK3 sustains EMT and stemness in
pancreatic cancer by regulating YAP and TAZ transcriptional
activity. Anticancer Res. 38:1937–1946. 2018.PubMed/NCBI
|
|
40
|
Wa Q, Li L, Lin H, Peng X, Ren D, Huang Y,
He P and Huang S: Downregulation of miR19a3p promotes invasion,
migration and bone metastasis via activating TGFβ signaling in
prostate cancer. Oncol Rep. 39:81–90. 2018.PubMed/NCBI
|
|
41
|
Yang Y, Ji C, Guo S, Su X, Zhao X, Zhang
S, Liu G, Qiu X, Zhang Q, Guo H and Chen H: The miR-486-5p plays a
causative role in prostate cancer through negative regulation of
multiple tumor suppressor pathways. Oncotarget. 8:72835–72846.
2017.PubMed/NCBI
|
|
42
|
Yamada Y, Nishikawa R, Kato M, Okato A,
Arai T, Kojima S, Yamazaki K, Naya Y, Ichikawa T and Seki N:
Regulation of HMGB3 by antitumor miR-205-5p inhibits cancer cell
aggressiveness and is involved in prostate cancer pathogenesis. J
Hum Genet. 63:195–205. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kanwal R, Plaga AR, Liu X, Shukla GC and
Gupta S: MicroRNAs in prostate cancer: Functional role as
biomarkers. Cancer Lett. 407:9–20. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nass D, Rosenwald S, Meiri E, Gilad S,
Tabibian-Keissar H, Schlosberg A, Kuker H, Sion-Vardy N, Tobar A,
Kharenko O, et al: MiR-92b and miR-9/9* are specifically expressed
in brain primary tumors and can be used to differentiate primary
from metastatic brain tumors. Brain Pathol. 19:375–383. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shiiyama R, Fukushima S, Jinnin M,
Yamashita J, Miyashita A, Nakahara S, Kogi A, Aoi J, Masuguchi S,
Inoue Y and Ihn H: Sensitive detection of melanoma metastasis using
circulating microRNA expression profiles. Melanoma Res. 23:366–372.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang J, Jia J, Zhao L, Li X, Xie Q, Chen
X, Wang J and Lu F: Down-regulation of microRNA-9 leads to
activation of IL-6/Jak/STAT3 pathway through directly targeting
IL-6 in HeLa cell. Mol Carcinog. 55:732–742. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mohammadi-Yeganeh S, Mansouri A and Paryan
M: Targeting of miR9/NOTCH1 interaction reduces metastatic behavior
in triple-negative breast cancer. Chem Biol Drug Des. 86:1185–1191.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Higashi T, Hayashi H, Ishimoto T, Takeyama
H, Kaida T, Arima K, Taki K, Sakamoto K, Kuroki H, Okabe H, et al:
miR-9-3p plays a tumour-suppressor role by targeting TAZ (WWTR1) in
hepatocellular carcinoma cells. Br J Cancer. 113:252–258. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Luo H, Zhang H, Zhang Z, Zhang X, Ning B,
Guo J, Nie N, Liu B and Wu X: Down-regulated miR-9 and miR-433 in
human gastric carcinoma. J Exp Clin Cancer Res. 28:822009.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Di Y, Li S, Wang L, Zhang Y and Dorf ME:
Homeostatic interactions between MEKK3 and TAK1 involved in
NF-kappaB signaling. Cell Signal. 20:705–713. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Guarino M: Epithelial-mesenchymal
transition and tumour invasion. Int J Biochem Cell Biol.
39:2153–2160. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Baigude H, Ahsanullah, Li Z, Zhou Y and
Rana TM: miR-TRAP: A benchtop chemical biology strategy to identify
microRNA targets. Angew Chem Int Ed Engl. 51:5880–5883. 2012.
View Article : Google Scholar : PubMed/NCBI
|
